Available online at www.sciencedirect.com
ScienceDirect
Diagnostic Microbiology and Infectious Disease 67 (2010) 392 – 394
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
www.elsevier.com/locate/diagmicrobio

# *Aspergillus* DNA contamination in blood collection tubes

Elizabeth Harrison[a,*], Thomas Stalhberger[a], Ruth Whelan[a], Michele Sugrue[b], John R. Wingard[b], Barbara D. Alexander[c], Sarah A. Follett[d], Paul Bowyer[a], David W. Denning[a]
for the Aspergillus Technology Consortium (AsTeC)[1]

[a]*Manchester Academic Health Science Centre, University Hospital of South Manchester, The University of Manchester, Southmoor Road, Manchester M23 9LT, United Kingdom*
[b]*Division of Hematology and Oncology, College of Medicine, University of Florida, USA*
[c]*Division of Infectious Diseases and International Health, Duke University Medical Center*
[d]*Myconostica Ltd, United Kingdom*

Received 7 January 2010; accepted 27 February 2010

**Abstract**

Fungal polymerase chain reaction (PCR)-based diagnostic methods are at risk for contamination. Sample collection containers were investigated for fungal DNA contamination using real-time PCR assays. Up to 18% of blood collection tubes were contaminated with fungal DNA, probably *Aspergillus fumigatus*. Lower proportions of contamination in other vessels were observed.
© 2010 Elsevier Inc. All rights reserved.

*Keywords:* *Aspergillus*; DNA; Blood collection tubes

The incidence of invasive aspergillosis is increasing among immunocompromised individuals with an estimated 1 million deaths worldwide (Maschmeyer and Haas, 2008). The need for a universally applicable rapid and sensitive diagnostic method is pressing (Denning, 1998). Polymerase chain reaction (PCR)-based detection of *Aspergillus* nucleic acids provides a well explored diagnostic technique that could fulfill these criteria (Chen et al., 2002, Perlin and Zhao, 2009). However, *Aspergillus* is ubiquitous in the environment and DNA contamination in a diagnostic assay can arise from dead or fragmented fungi. Given the costs and side effects of the preferred antifungal therapeutics (Menzin et al., 2009), even very low levels of false-positive results or contamination have serious consequences. The most convenient source of material for diagnosis is blood. An 8% contamination rate in over 3000 fungal PCR assays performed on whole blood over 2 years has been reported (Loeffler et al., 1999). Contaminating DNA from 12 different *Aspergillus* spp. caused a false-positive rate of 19% with sources of contamination including DNA extraction and PCR reagents (Palmer et al., 2001).

We investigated the prevalence of fungal DNA contamination originating from blood collection tubes and a variety of other clinically relevant vessels from a range of manufacturers using a DNA extraction kit that has been proven free from fungal DNA (data not shown) (MycXtra; Myconostica, Manchester, United Kingdom). Extracted DNA was tested using a quality controlled commercial molecular beacon (MB) real-time PCR assay that detects *Aspergillus* and *Penicillium* spp. (FXG:Resp (Asp+), Myconostica). Positive samples were screened using a second PCR assay with a TaqMan (TM) probe specific for *Aspergillus fumigatus* only.

Collection vessels tested and rates of contamination detected are listed in Table 1. To test for microbiologic

* Corresponding author. Tel: +44-0-161-291-2909; fax: +44-0-161-291-5806.
*E-mail address:* liz.harrison@manchester.ac.uk (E. Harrison).

[1] AsTeC principle investigators: John R. Wingard, MD, and Michele Sugrue, MS, MT(ASCP)SBB, University of Florida, Gainesville, FL; Barbara D. Alexander, MD, MHS, Duke University Medical Center, Durham, NC; Angela Caliendo, MD, PhD, and G. Marshall Lyon, MD, Emory University Hospital, Atlanta, GA; Lindsey Baden, MD, and Francisco Marty, MD, Harvard University and Brigham and Women's Hospital, Boston, MA; L. Joseph Wheat, MD, MiraVista Diagnostics, Indianapolis, IN; David Denning, MD, The University of Manchester, Manchester, United Kingdom; Ming-Hong Nguyen, MD, and Cornelius J. Clancy, MD, University of Pittsburgh Medical Center, Pittsburgh, PA.

0732-8893/$ – see front matter © 2010 Elsevier Inc. All rights reserved.
doi:10.1016/j.diagmicrobio.2010.02.028

contamination, we added sterile phosphate buffered saline (PBS)–Tween 80 (1 mL) to each vessel and agitated it on a vortex mixer for 1 min. An aliquot (100 μL) was then spread onto Sabouraud dextrose agar plates and incubated at 30 °C for 2 weeks. To test for fungal DNA contamination, we added molecular-grade sterile water (1 mL) to each vessel and agitated it on a vortex mixer for 1 min followed by DNA extraction with the MycXtra kit. Tubes containing liquid additives had 1 mL of water added and 1 mL of total liquid removed for DNA extraction. DNA extraction was performed in a laboratory that is environmentally monitored for fungal contamination. Sabouraud dextrose agar plates were left open on the laboratory bench top during extraction to measure the local airborne fungal flora and incubated at 30 °C for 2 weeks. After DNA extraction, 5 μL of the extract was tested in an *Aspergillus* MB real-time PCR assay (Myconostica) using an ABI 7500 (Applied Biosystems, Foster City, CA), which has a detection limit of 50 target 18S rRNA copies, equating to approximately 1 genome (Herrera et al., 2009, Tyagi and Kramer, 1996). Each multiplex PCR included primers and MBs to detect *Aspergillus* DNA with an internal amplification control to assess the occurrence of inhibition. PCR-positive samples and controls were tested with an *A. fumigatus* TM assay described elsewhere (Challier et al., 2004). PCR setup was performed under sterile laminar flow using a dedicated hood, equipment, and laboratory coats. The area was regularly disinfected and monitored for fungal spores using settle plates and an air sampler. *Aspergillus* DNA-free sterile supplies of water, pipettes, pipette tips, and plasticware were maintained throughout.

No fungal colonies grew from the collection vessels tested. All DNA extraction controls were culture and PCR negative. The frequency of MB PCR-positive results are listed in Table 1. Ct values ranged from 32.5 to the limit of detection (LOD) of 38.1. The TM assay showed 96% (48/50) agreement with samples that were MB positive.

Of the whole blood collection tubes, 12 of 85 (14%) spray dried and 19 of 100 (19%) liquid tubes were contaminated. Of the serum blood collection tubes, 5 of 85 (6%) containing a spray dried clot activator and 11 of 75 (15%) without additives were contaminated. One of 20 (5%) RNA*Later* reagent aliquots and 2 of 50 (4%) of the urine collection containers were contaminated. No Cell Preparation Tube, PaxGene RNA tube, broncheoalveolar lavage (BAL) collection tube, cryovial, or pipette tip was contaminated.

The results presented highlight a problem in DNA-based detection methods for rapid diagnosis of fungal infection. PCR is highly sensitive and appears to reveal the presence of fragments of fungi containing DNA in microbiologically sterile containers. The fill volume of each tube is typically larger than the 1 mL of sterile water used here, and the results probably overestimate the problem in the clinic. However, blood tubes are often under filled, and small volumes are the norm in pediatric practice. Five of the 50 (10%) positive PCR signals were strong (Ct values <34), suggesting that the assay would still be positive after dilution with larger volumes.

The MB assay detects both *Aspergillus* spp. and some *Penicillium* spp. and does not discriminate between specific species (unpublished data). The TM assay is specific for *A. fumigatus* targeting the 28S rDNA region. Agreement between assays on 96% of positive samples reinforces the conclusion that the results are robust. (The 2 samples that were TM negative were close to the LOD with the MB assay.) It is likely that most of the contaminated tubes contained *A. fumigatus* DNA. This is problematic in the clinical setting.

Table 1
Collection vessels tested, manufacturer, number tested, and frequency of *Aspergillus* PCR positivity

| Type of vessel | Additive | Manufacturer | Lots tested | Tested per lot (total tested) | MB PCR positive (%) |
|---|---|---|---|---|---|
| Whole blood collection tube, 2 mL | $K_2$EDTA (spray dried) | BD Vacutainer, Franklin Lakes, NJ | 1 | 10 (10) | 0 (0) |
| Whole blood collection tube, 6 mL | $K_2$EDTA (spray dried) | BD Vacutainer | 3 | 25 (75) | 12 (16) |
| Whole blood collection tube, 6 mL | $K_3$EDTA (liquid) | BD Vacutainer | 1 | 25 (25) | 0 (0) |
| Whole blood collection tube, 7 mL | $K_3$EDTA (liquid) | BD Vacutainer | 3 | 25 (75) | 19 (15) |
| Serum blood collection tube, 3 mL | Clot activator (spray dried) | BD Vacutainer | 1 | 10 (10) | 0 (0) |
| Serum blood collection tube, 6 mL | Clot activator (spray dried) | BD Vacutainer | 3 | 25 (75) | 5 (7) |
| Serum blood collection tube, 6 mL | None | BD Vacutainer | 2 | 25 (50) | 11 (18) |
| Serum blood collection tube, 10 mL | None | BD Vacutainer | 1 | 25 (25) | 0 (0) |
| Cell Preparation Tube | Sodium citrate and Ficoll | BD Vacutainer | 3 | 6 (18) | 0 (0) |
| PaxGene RNA | Multiple[a] | PreAnalytiX, Erembodegem, BE | 2 | 6 (12) | 0 (0) |
| RNA*later* | RNA stabilization reagent | Ambion, Foster City, CA | 2 | 10 (20) | 1 (5) |
| BAL collection container, 40 mL | | Busse, Hauppauge, NY | 2 | 12 (24) | 0 (0) |
| Urine collection container (sterile cup only) | | Medline, Mundelein, IL | 1 | 25 (25) | 2 (8) |
| Urine collection container (sterile mid stream kit) | | Medline | 1 | 25 (25) | 0 (0) |
| Cryovial container, 2 mL | | Simport, Quebec City, Canada | 1 | 10 (10) | 0 (0) |
| Cryovial container, 3 mL | | Simport | 2 | 10 (20) | 0 (0) |
| Pipette tips, 1000 μL | | Eppendorf, Hamburg, DE | 2 | 5 (10) | 0 (0) |

[a] PaxGene additives: tetradecyltrimethylammonium oxalate solution, tartaric acid, and undisclosed nonhazardous substances.

Another explanation for contamination is introduction of DNA during extraction or PCR setup. In this study, the DNA extraction and PCR setup procedures were rigorously controlled using settle plates, negative extraction controls, and no-template PCR controls. All controls were culture and PCR negative, and it is most likely that the contamination arose from the collection vessels.

These data suggest that between 0% and 18% of blood collection tubes are contaminated with *Aspergillus* spp. DNA with possible contamination of urine collection vessels and RNA stabilization reagents. We conclude that development of fungal real-time PCR will require consideration of the ubiquitous nature of fungal flora and DNA and the impact of any contamination on the sensitivity of the technique. This result has serious implications for the development of PCR diagnostics for fungal disease using standard collection vessels.

## Acknowledgments

The present work was supported in part by National Institute of Health - National Institute of Allergy and Infectious Diseases (NIH-NIAID) K24-AI072522 (Barbara D. Alexander) and NIH-NIAID N01-AI70023/HHSN266200700023C (AsTeC).

## References

Challier S, Boyer S, Abachin E, Berche P (2004) Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. *J Clin Microbiol* 42(2):844–846.

Chen SC, Halliday CL, Meyer W (2002) A review of nucleic acid-based diagnostic tests for systemic mycoses with an emphasis on polymerase chain reaction-based assays. *Med Mycol* 40:333–357.

Denning DW (1998) Invasive aspergillosis. *Clin Infect Dis* 26:781–803.

Herrera ML, Vallor AC, Gelfond JA, Patterson TF, Wickes BL (2009) Strain-dependent variation in 18S ribosomal DNA Copy numbers in *Aspergillus fumigatus*. *J Clin Microb* 47(5):1325–1332.

Loeffler J, Hebart H, Bialek R, Hagmeyer L, Schmidt D, Serey FP, Hartmann M, Eucker J, Einsele H (1999) Contaminations occurring in fungal PCR assays. *J App Microbiol* 37(4):1200–1202.

Maschmeyer G, Haas A (2008) The epidemiology and treatment of infections in cancer patients. *Int J Antimicrob Agents* 31: 193–197.

Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G (2009) Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. *Am J Health Syst Pharm* 66:1711–1717.

Palmer J, Francesconi A, Kasai M, Walsh TJ, Orle K (2001) Sources of false positive *Aspergillus* DNA by PCR from normal human blood. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago, Ill.) Dec 16–19; abstract no. J-844.

Perlin DS, Zhao Y (2009) Molecular diagnostic platforms for detecting *Aspergillus*. *Med Mycol* 47(Suppl 1):S223–S232.

Tyagi S, Kramer FR (1996) Molecular beacons: probes that fluoresce upon hybridization. *Nat Biotechnol* 14:303–308.